"Zetiq" Reports Success in Clinical Trial for Identification of Bladder Cancer

Zetiq's technology, known as CellDetect®, uses dual analysis of both color discrimination and morphological analysis to differentiate between neoplastic and non neoplastic cells.

Bladder cancer is one of the most commonly occurring cancers in the world. In the US, bladder cancer is the fifth most common neoplasm and the 12^th leading cause of cancer death, with over 70,000 annual new identified cases of bladder cancer and over 14,000 annual deaths as a result of this disease. It is estimated that over 500,000 patients in the U.S. and over two million patients worldwide are living with bladder cancer. Males are affected four times more frequently than women. The overall 5-year relative survival rate is 97%   when the disease is identified at its earliest in situ stage, and drops to 6% when the disease is diagnosed at its distant stage, stressing the importance of early diagnosis.

No effective screening technique is available for detection of bladder cancer. Moreover, bladder cancer has the highest rate of recurrence among all US malignancies (over 75%), and there exists a high demand for effective monitoring programs. 

Dr. Ami Eyal – Medical Director of Zetiq and CEO of Bio-light, its parent company says: "The CellDetect® technologies' ability to detect cancer cells is exceptional. These findings attest to the range of applications for the company's technology and open the door for expanding our efforts to develop diagnostic tools for additional cancer indications. The results of this trial confirm that Zetiq has the potential to develop novel and effective products for early diagnosis of bladder cancer alongside cervical cancer, and other indications. The company plans to further develop products for early diagnosis, and monitoring, of bladder cancer."

Zetiq is a subsidiary of Bio-Light Life Science Investments, a management and holding company specializing in biomedical technologies. Bio-Light is traded on the Tel Aviv Stock Exchange under the symbol TASE:BOLT.

About Zetiq:

Zetiq Technologies Ltd. develops effective cancer diagnostic tools. There is a significant medical need for early stage diagnostic tools for screening, monitoring or diagnosing cancer. Zetiq offers unique advantages in this market with its proprietary CellDetect® technology for differential staining and morphological visualization to differentiate between non cancer cells and a wide variety of cancer indications. The Company's products alleviate the process of locating and identifying suspected cancer cells, reduce error, simplify the process and have a potential to be fully automated.

Zetiq is a subsidiary of Bio-Light Life Science Investments, a management and holding company specializing in biomedical technologies. Bio-Light is traded on the Tel Aviv Stock Exchange under the symbol TASE: BOLT.

For further information please contact:

Dr. Adi Elkeles

CEO

Zetiq Technologies Ltd.

www.zetiq.co.il

adi@bio-light.co.il